DNA Script SAS nabbed $165 million in a series C fundraising round to support commercialization of the company’s Syntax platform and expand its portfolio of products powered by enzymatic DNA synthesis. DNA Script has raised a total of $280 million to date.
DNA Script SAS raised a $50 million extension to its series B financing, for a total yield of $89 million. Paris-based DNA Script has earmarked the funds to advance the development of its suite of enzymatic DNA synthesis (EDS) technologies and support the commercial launch of its Syntax DNA benchtop printer.